KMT2A and acute myeloid leukemia: Along with mounting evidence for the role of BCL-2 in AML cell survival, early preclinical studies into venetoclax as a monotherapy in AML cell lines, patient samples, and a murine xenograft model demonstrated on-target cell killing9, with particular sensitivity to venetoclax seen in AML cells harboring the MLL fusion genes and in acute promyelocytic leukemia (APL) cells85.